Finally, our investigations in three different pair of cancer cell lines (originating from breast, lung and prostate) with different p53 status demonstrated that the p53 status-associated survivin expression is an essential parameter to predict bortezomib resistance irrespective of the origin of the cancer cell. The gene discussed is TP53; the disease is cancer.